Ignite Creation Date:
2025-12-25 @ 5:00 AM
Ignite Modification Date:
2025-12-26 @ 4:00 AM
Study NCT ID:
NCT00709618
Status:
TERMINATED
Last Update Posted:
2014-07-14
First Post:
2008-07-02
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-06
Start Date Type:
None
Primary Completion Date:
2012-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-05
Completion Date Type:
ACTUAL
First Submit Date:
2008-07-02
First Submit QC Date:
None
Study First Post Date:
2008-07-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-12-13
Results First Submit QC Date:
None
Results First Post Date:
2013-01-18
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-06-30
Last Update Post Date:
2014-07-14
Last Update Post Date Type:
ESTIMATED